SELL Aurobindo Pharma — Macquarie, 06 Aug 2026

SELLAurobindo Pharma

byMacquarieHorizon: 1–3 months6 Aug 2026via CNBC Awaaz.

Entry₹1,625Inferred

Target₹1,300

Total upside +20.00%

Stop lossNot given

CMP₹1,653.12d ago

Active-1.73%+21.36%upside left 2 mo left

Follow Macquarie for new callsGet alerts Watch AUROPHARMA for new buy/sell callsGet alerts

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this SELL call — facts from public sources, machine-classified. Not investment advice.

As of 7 Sept, 4:55 am IST

8 supporting8 neutral21 opposing

Supports the SELL call (8)

MACD below its signal line — bearish momentum

Technicals · macd·6 Sept · today

USFDA Issues Three Observations To Aurobindo Pharma Arm's Facility In Andhra

NewsNdtv-Profit·28 Aug · 1w ago

Aurobindo Pharma US subsidiary Lannett Company LLC faces 4 observations from the USFDA

NewsLivemint·24 Aug · 2w ago

Aurobindo Pharma shares in focus after USFDA closes Raleigh unit inspection with 11 observations

NewsCnbc-Tv18·17 Aug · 3w ago

Aurobindo Pharma shares fall after USFDA issues warning letter to Eugia's Unit 1

NewsCnbc-Tv18·14 Aug · 3w ago

Neutral / worth noting (8)

Aurobindo Pharma Ltd's wholly owned subsidiary, Apitoria Pharma Private Limited, has incorporated a new wholly owned subsidiary named Ávogent Lifesciences Private Limited.

BSE · Company Update·1 Sept · 5d ago

Aurobindo Pharma’s API plant gets three US FDA observations after inspection

NewsCnbc-Tv18·28 Aug · 1w ago

Here's why these four pharma stocks are in focus today

NewsCnbc-Tv18·24 Aug · 2w ago

Weighs against the SELL call (21)

8 advisors have active long-term BUY calls on this stock, with 2 issued in the last 14 days

Advisor consensus · adjacent horizon·1 Sept · 5d ago

Aurobindo Pharma gains over 3% as subsidiary launches generic Advair Diskus in US; stock up 41% YTD

NewsEt-Markets·31 Aug · 6d ago

Aurobindo Pharma's subsidiary, Lannett Company LLC, has launched a generic version of Advair Diskus® in the US. This product is used to treat asthma and COPD.

NSE · Press Release·31 Aug · 6d ago

Aurobindo Pharma's subsidiary, Lannett Company LLC, has launched a generic version of Advair Diskus in the US. This marks the first product from Aurobindo's inhalation pipeline to be commercialized in

BSE · Company Update·31 Aug · 6d ago

Aurobindo Pharma Share Price Gains As USFDA Concludes Inspection At Subsidiary Lannett's Unit

NewsNdtv-Profit·24 Aug · 2w ago

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.